Navigation Links
ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
Date:1/19/2011

SAN DIEGO, Jan. 19, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011 for the review of the Exelbine (ANX-530) New Drug Application (NDA). The acceptance of the Exelbine NDA is the FDA's determination that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for the FDA to complete its review of the NDA.  

"With a September PDUFA date established in the Day 74 letter from the FDA, we look forward to working closely with the Agency on moving Exelbine toward approval this year," said Brian M. Culley, Chief Executive Officer of ADVENTRX.

About Exelbine

ADVENTRX is seeking approval of Exelbine for the same indications as Navelbine®, a branded formulation of vinorelbine, including non-small cell lung cancer.  ADVENTRX submitted the NDA as a 505(b)(2) application that relies in part on the FDA's findings of safety and effectiveness of a reference drug.  The Exelbine NDA includes data from one clinical bioequivalence study designed to assess the pharmacokinetic equivalence of Exelbine and Navelbine, the reference drug.  In this clinical bioequivalence study, Exelbine and the reference drug were determined by ADVENTRX to be bioequivalent.  

ADVENTRX retains exclusive worldwide rights to Exelbine, other than in South Korea, China, Hong Kong, Macau and Taiwan.  In March 2010, the FDA conditionally accepted "Exelbine" as the proposed proprietary name for ANX-530.  The United States Patent and Trademark Office has allowed patent claims related to Exelbine, which claims issued in January 2011 and will expire in November 2027.  

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuti
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... NEW YORK and PLAINSBORO, ... Nordisk announced today its support of the National ... in Care , which provides support to people ... the physical and psychosocial challenges that can impede ... of six modules, Communication With Your Provider ...
(Date:9/18/2014)... and MELBOURNE, Australia , Sept. ... Biopharma today announced the appointments of Dr. Ashraf ... D.V.M ., M.S., to its Board of Directors. Dr. ... Affairs Finance at Genentech and Chief Financial Officer for ... as Vice President and Global Head of Business Development ...
(Date:9/18/2014)... NEW YORK , Sept. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... James to the position of  Senior Director of ... Clinical Research, Mr. James has established and led successful ... Europe , to facilitate the clinical development ...
Breaking Medicine Technology:Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... 2011 Egenix, Inc. -- Donald Fresne, CEO ... appointment of Nils Bergenhem, PhD as President and ... of drug development experience to the company and ... between equally-sized companies, as well as between biotech ...
... Caremark Corporation (NYSE: CVS ) will be ... at 8:30 a.m. (ET) with analysts and investors to ... (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) An audio webcast of the ... Relations portion of the CVS Caremark Web site for ...
Cached Medicine Technology:Nils Bergenhem, PhD - Newly Appointed President and Chief Scientific Officer of Egenix, Inc. 2CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call 2
(Date:9/18/2014)... Clinical trial report, “Edema Global Clinical Trials ... trial scenario. This report provides elemental information and data ... an overview of the trial numbers and their recruitment ... the globe. The databook offers a preliminary coverage of ... of the sponsors and also provides briefing pertaining to ...
(Date:9/18/2014)... This past August, Narconon Louisiana New Life ... the kissing booth during the West Feliciana Animal Humane Society fundraiser ... have loved animals my whole life and have always had animals ... strays who needed a home. Supporting an animal shelter allows ... all home!” , The CEO of Narconon Louisiana was there not ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Relias Learning, the ... and human services markets, today announced it has been named ... growing private companies in America. , In the three-year period ... moved up almost 2,000 spots on the Inc. 5000 list ... , “The industries we serve continue to grow, ...
(Date:9/18/2014)... The new BuildClean™ Dust Control ... and homeowners alike as it eliminates the top ... causes potential health issues, and makes it “unlivable” ... system allows contractors to virtually eliminate airborne dust ... remodeling tasks. , BuildClean removes up to 90 ...
(Date:9/18/2014)... Salamon HealthDay Reporter ... midlife may be associated with increased odds of developing ... new research suggests. The study, which did not ... also suggested that the migraine-Parkinson,s association was stronger in ... a warning sign of a pending attack that includes ...
Breaking Medicine News(10 mins):Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3
... a newborn baby going under the knife to repair a ... work begins for parents. University of Alberta nursing professor Gwen ... a former pediatric cardiology nurse; she wanted to find out ... per cent convinced that health-care professionals get what these parents ...
... 26 The Providence Service,Corporation (Nasdaq: PRSC ) ... financial advisor. , In ... strategic,options relating to, among other things, delevering its debt, growing ... UBS,Investment Bank has been retained in connection with selling certain,non-strategic ...
... Stylists, beauticians may be affected by phthalates in these ... -- Mothers exposed to a common hairspray chemical while ... born with an abnormally placed urinary opening, a new ... fragrances, and nail and hair products contain chemicals called ...
... are misaligned and point outward are at significantly ... adulthood, according to findings of a Mayo Clinic ... ( http://pediatrics.aappublications.org/cgi/content/full/122/5/1033 ), the official journal of the ... examined the medical records of 407 patients with ...
... it,s cheaper and less time-consuming than in-person visits, study ... counseling may be as effective as face-to-face counseling in ... University of Florida study included 234 obese women, ages ... Florida. , All the women completed a six-month weight-loss ...
... Public engagement practitioners from across the world are to ... be held in South Africa, organised by the Wellcome ... engage to empower" will take place from 2-5 ... Studies, KwaZulu-Natal. It will bring together practitioners working in ...
Cached Medicine News:Health News:Parents are the unsung heroes 2Health News:Providence Service Corporation Retains UBS Investment Bank as its Financial Advisor in Connection With the Sale of Certain Non-Strategic Assets 2Health News:Over-the-Phone Weight Loss Counseling Works 2Health News:International workshop aims to boost public engagement work in developing countries 2Health News:International workshop aims to boost public engagement work in developing countries 3